- Home
- ICU vs BIAF Comparison
ICU vs BIAF Comparison
Compare ICU & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- BIAF
- Stock Information
- Founded
- ICU 2018
- BIAF 2014
- Country
- ICU United States
- BIAF United States
- Employees
- ICU N/A
- BIAF N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ICU Health Care
- BIAF Health Care
- Exchange
- ICU Nasdaq
- BIAF Nasdaq
- Market Cap
- ICU 10.4M
- BIAF 12.2M
- IPO Year
- ICU N/A
- BIAF 2022
- Fundamental
- Price
- ICU $1.18
- BIAF $0.27
- Analyst Decision
- ICU
- BIAF Hold
- Analyst Count
- ICU 0
- BIAF 1
- Target Price
- ICU N/A
- BIAF N/A
- AVG Volume (30 Days)
- ICU 144.0K
- BIAF 9.3M
- Earning Date
- ICU 05-14-2025
- BIAF 05-15-2025
- Dividend Yield
- ICU N/A
- BIAF N/A
- EPS Growth
- ICU N/A
- BIAF N/A
- EPS
- ICU N/A
- BIAF N/A
- Revenue
- ICU $428,000.00
- BIAF $8,809,228.00
- Revenue This Year
- ICU $648.15
- BIAF N/A
- Revenue Next Year
- ICU $100.00
- BIAF $19.99
- P/E Ratio
- ICU N/A
- BIAF N/A
- Revenue Growth
- ICU N/A
- BIAF 78.40
- 52 Week Low
- ICU $1.11
- BIAF $0.16
- 52 Week High
- ICU $13.85
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- ICU 35.77
- BIAF 44.90
- Support Level
- ICU $1.13
- BIAF $0.24
- Resistance Level
- ICU $1.34
- BIAF $0.50
- Average True Range (ATR)
- ICU 0.07
- BIAF 0.06
- MACD
- ICU 0.00
- BIAF 0.01
- Stochastic Oscillator
- ICU 23.81
- BIAF 28.60
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.